Maersk signs deal with Covaxx to transport 1 billion Covid-19 vaccines

Maersk announced that it will transport the vaccines against Covid-19 developed by the American company Covaxx.  According to the carrier, this is an agreement that establishes integrated logistics to allow the efficient distribution of the Covaxx Covid-19 vaccine worldwide. The goal is to deliver up to 1 billion doses of the synthetic vaccine by 2021.

The agreement establishes a framework for all transportation and supply chain services that will be needed to deliver the US company’s UB-612 vaccines worldwide once the drug is approved by regulatory authorities. The financial terms of the agreement have not been revealed.

Covaxx has pre-commitments for more than 100 million doses of the UB-612 vaccine. In September, the company announced an agreement with Dasa, the largest diagnostic medicine company in Brazil, to conduct a large-scale clinical trial of human effectiveness.

Maersk will oversee all vaccine logistics activities to ensure efficient transport to developing countries. The contract provides for end-to-end supply chain management: packaging; transportation via land, sea, and air; storage; and distribution. This will ensure a quality vaccine, as it requires temperature control.

Covaxx plans to manufacture 100 million doses of UB-612 in early 2021 and 1 billion doses by the end of 2021. The vaccine components will allow the use of existing cold-chain storage and distribution channels, as the Covaxx vaccine does not require additional infrastructure such as -80 ° C freezers or liquid nitrogen tanks to store materials at extreme temperatures.

Source: Port Portal

Sharing is caring!